Department of Gastroenterology, Alfred Hospital, The Alfred55 Commercial Rd, Melbourne, 3004, Australia.
Department of Radiology, Alfred Hospital, Melbourne, Australia.
Cardiovasc Intervent Radiol. 2021 Feb;44(2):247-253. doi: 10.1007/s00270-020-02666-4. Epub 2020 Oct 13.
Irreversible electroporation (IRE) is a non-thermal ablation technique for unresectable hepatocellular carcinoma (HCC) not amenable to standard thermal ablation. The aim of this study was to report our longer-term outcomes using this treatment modality.
We identified all patients at our institution who underwent IRE for HCC between December 2008 and October 2019 as recommended after multi-disciplinary team review. Demographic, clinical, tumour response and survival data up until 1 March, 2020 were analysed. The primary outcome was local recurrence-free survival (LRFS) in patients who had a complete response (CR). Secondary outcomes included CR rates, procedure-related complications and the incidence of death or liver transplantation.
A total of 23 patients (78% males, median age 65.2 years) received IRE therapy to 33 HCC lesions during the study period with the median tumour size being 2.0 cm (range 1.0-5.0 cm). Twenty-nine (87.9%) lesions were successfully ablated after one (n = 26) or two (n = 3) procedures. The median follow-up time for these lesions was 20.4 months. The median overall LRFS was 34.5 (95% CI 24.8 -) months with a 6- and 12-month LRFS of 87.9% (95% CI 75.8-100) and 83.6% (95% CI 70.2-99.7), respectively. Tumours < 2 cm had a 12-month LRFS of 100% (95% CI 100-100).
IRE appears to be an efficacious local ablative method for early stage HCC not amenable to standard ablative techniques, with very good CR rates and longer-term LRFS, particularly for smaller lesions. Further studies comparing this technique to more widely accepted ablative methods such as radiofrequency and microwave ablation are warranted.
不可逆电穿孔(IRE)是一种非热消融技术,适用于不适合标准热消融的不可切除的肝细胞癌(HCC)。本研究旨在报告我们使用这种治疗方式的长期结果。
我们在多学科团队审查后,确定了 2008 年 12 月至 2019 年 10 月期间在我院接受 IRE 治疗的所有 HCC 患者。分析了截至 2020 年 3 月 1 日的人口统计学、临床、肿瘤反应和生存数据。主要结果是完全缓解(CR)患者的局部无复发生存(LRFS)。次要结果包括 CR 率、与手术相关的并发症以及死亡或肝移植的发生率。
在研究期间,共有 23 名(78%为男性,中位年龄 65.2 岁)患者的 33 个 HCC 病变接受了 IRE 治疗,肿瘤大小中位数为 2.0cm(范围 1.0-5.0cm)。29 个(87.9%)病变在一次(n=26)或两次(n=3)手术后成功消融。这些病变的中位随访时间为 20.4 个月。中位总体 LRFS 为 34.5 个月(95%CI 24.8-),6 个月和 12 个月的 LRFS 分别为 87.9%(95%CI 75.8-100)和 83.6%(95%CI 70.2-99.7)。肿瘤<2cm 的 12 个月 LRFS 为 100%(95%CI 100-100)。
IRE 似乎是一种有效的早期 HCC 局部消融方法,适用于不适合标准消融技术的患者,具有非常高的 CR 率和长期 LRFS,特别是对于较小的病变。进一步比较该技术与更广泛接受的消融方法(如射频和微波消融)的研究是必要的。